Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bustoros

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
American Journal of Hematology|February 19, 2019
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupMark Bustoros, Efstathios Kastritis, Romanos Sklavenitis-Pistofidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
The Journal of Clinical Investigation|March 21, 2018
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppressionYawara Kawano, Oksana Zavidij, Jihye Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
Nature Cancer|January 7, 2021
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaOksana Zavidij, Nicholas J Haradhvala, Tarek H Mouhieddine, et al.
The Lancet. Haematology|March 28, 2022
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort studyHabib El-Khoury, David J Lee, Jean-Baptiste Alberge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2020
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionMark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nature Communications|January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trialOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
American Journal of Hematology|February 19, 2019
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupMark Bustoros, Efstathios Kastritis, Romanos Sklavenitis-Pistofidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
The Journal of Clinical Investigation|March 21, 2018
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppressionYawara Kawano, Oksana Zavidij, Jihye Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
Nature Cancer|January 7, 2021
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaOksana Zavidij, Nicholas J Haradhvala, Tarek H Mouhieddine, et al.
The Lancet. Haematology|March 28, 2022
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort studyHabib El-Khoury, David J Lee, Jean-Baptiste Alberge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2020
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionMark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Pageof 4